CDMO Cytovance Biologics and CDO Celltheon Partner to Offer a Complete, US-based Platform Solution for mAbs and Difficult-to-Express Proteins
30 Julio 2024 - 5:15AM
Business Wire
- This partnership provides the industry with an integrated
solution for customers seeking to outsource cell line development
through to cGMP manufacturing of their mammalian-expressed products
leveraging the latest available technologies.
To better support the rising demand for development and
manufacturing of more complex biologics particularly in US-based
facilities, Oklahoma-based Cytovance Biologics and California-based
Celltheon have partnered to deliver an improved, integrated
solution that combines Celltheon’s industry-leading CHO-K1-based
cell line development platform and Cytovance’s fully integrated
CDMO services.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240730811788/en/
“We have seen firsthand the improved timelines,
manufacturability, and product yield that Celltheon’s expression
technologies provide to their customers, and we are excited to now
be able to welcome them and their novel therapeutics into our cGMP
facilities,” explained Axel Schleyer, CCO of Cytovance. “This
partnership is also part of our strategic effort to expand our
customer’s options for finding the perfect cell line for their
target molecule, so they can reach the clinic and the market
faster.”
Under the arrangement, Cytovance customers have access to
Celltheon's proprietary OmniCHO™ Platform for early-stage transient
protein expression, their CELLTHEON SMART™ Platform for later
stable clone development, as well as their optimized pGL™ Vectors
and GOLDILOCKS™ transposase system. Once the upstream development
stage is completed, Celltheon’s customers will now be able to
transfer their products into downstream development and take them
all the way through cGMP manufacturing at Cytovance’s dedicated
mammalian facilities, with scale up options of 1000L and 2000L
bioreactors.
“We are delighted to collaborate with the Cytovance team to
further expand our partnerships and provide access to the CELLTHEON
SMART™ Cell Line Development Platform, which serves as a critical
starting point in the complex biologics manufacturing workflow,”
shared Nikhil Goel, CTO of Celltheon. “Cytovance is building a
comprehensive biologics manufacturing solution, and this
collaboration enables both companies to extend a complete platform
offering to a broader audience.”
Celltheon is the latest organization that Cytovance has added to
its trusted network built through best-of-breed partnerships.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730811788/en/
For Cytovance media inquiries, please contact:
sworcester@elementcg.co
For Celltheon media inquiries, please contact:
divya@celltheon.com